Om

Veraxa Biotech AG is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer therapies. The company works on antibody-drug conjugates and bispecific antibody formats, using proprietary screening and bioconjugation technologies to create targeted oncology candidates. Its current pipeline centers on drug programs in acute myeloid leukemia and other cancer indications, reflecting a focus on precise, mechanism-driven treatment approaches. Veraxa Biotech AG also develops platform capabilities intended to support the identification, engineering, and optimization of therapeutic antibodies for internal programs and collaborative partnerships. Based in Zurich, Switzerland, with research and development operations in Heidelberg, Germany, the company operates within the oncology biotechnology market and contributes to the broader advancement of next-generation biologic medicines.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I VERAXA BIOTECH HOLDING MED ENDAVU: Køb Veraxa Biotech Holding ($VRXA) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Veraxa Biotech Holding, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.